Clinical characteristics of study populations
| Characteristics | Values |
| Disease duration, mean ± SD | 8.05 ± 7.11 yr |
| Active diseasea | 83.6% |
| Extra-articular manifestations | 25.8% |
| Nodules | 24.2% |
| Sicca | 6.3% |
| Pulmonary fibrosis | 4.7% |
| Joint replacements | 21.1% |
| Tobacco yes/no | 23/77% |
| DMARDs naïve | 18.0% |
| Medications | |
| Corticosteroids | 51.6% |
| Methotrexate | 62.5% |
| Hydroxychloroquine | 38.3% |
| Sulfasalazine | 8.6% |
| TNF inhibitors | 21.1% |
| Characteristics | Values |
| Disease duration, mean ± SD | 8.05 ± 7.11 yr |
| Active diseasea | 83.6% |
| Extra-articular manifestations | 25.8% |
| Nodules | 24.2% |
| Sicca | 6.3% |
| Pulmonary fibrosis | 4.7% |
| Joint replacements | 21.1% |
| Tobacco yes/no | 23/77% |
| DMARDs naïve | 18.0% |
| Medications | |
| Corticosteroids | 51.6% |
| Methotrexate | 62.5% |
| Hydroxychloroquine | 38.3% |
| Sulfasalazine | 8.6% |
| TNF inhibitors | 21.1% |
Active disease defined by FDA criteria (presence of three or more of the following: morning stiffness (>45 min), swollen joints (>3), tender joints (>6), and sed rate (>28 mm).